Our data showed the HFCR treatment, which decreased the COX-2 protein level, not only attenuated obesity-related increase in liver oxidative damage, but indicated a suppression of elevated liver contents of TBARS, an index of oxidative damage. Here, PTGS2 is linked to obesity due to melanocortin 4 receptor deficiency.